Perrigo Company plc Amortization of Deferred Hedge Gains
Perrigo Company plc (PRGO) reported Amortization of Deferred Hedge Gains of -$10.30 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfDeferredHedgeGains · last filed 2026-08-05
- Perrigo Company plc amortization of deferred hedge gains for the quarter ending 2026-06-27 was -$5.40M.
- Perrigo Company plc amortization of deferred hedge gains for the quarter ending 2026-03-28 was -$4.90M.
- Perrigo Company plc amortization of deferred hedge gains for the quarter ending 2025-12-31 was -$5.50M.
- Perrigo Company plc amortization of deferred hedge gains for the quarter ending 2025-09-27 was -$5.70M.
- Perrigo Company plc amortization of deferred hedge gains for fiscal 2025 was -$23.80M.
- Perrigo Company plc amortization of deferred hedge gains for fiscal 2024 was -$10.10M, a 694.12% decline from fiscal 2023.
- Perrigo Company plc amortization of deferred hedge gains for fiscal 2023 was $1.70M.
| Period end | Amortization of Deferred Hedge Gains 3 month | Amortization of Deferred Hedge Gains 6 month | Amortization of Deferred Hedge Gains 9 month | Amortization of Deferred Hedge Gains 12 month |
|---|---|---|---|---|
| 2026-06-27 | -$5.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$10.30M 10-Q · filed 2026-08-05 | -$15.80M derived: sum of 3 quarters · filed 2026-08-05 | -$21.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | -$4.90M 10-Q · filed 2026-05-06 | -$10.40M derived: sum of 2 quarters · filed 2026-05-06 | -$16.10M derived: sum of 3 quarters · filed 2026-05-06 | -$22.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$11.20M derived: sum of 2 quarters · filed 2026-02-26 | -$17.40M derived: sum of 3 quarters · filed 2026-08-05 | -$23.80M 10-K · filed 2026-02-26 |
| 2025-09-27 | -$5.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$11.90M derived: sum of 2 quarters · filed 2026-08-05 | -$18.30M 10-Q · filed 2025-11-05 | -$37.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | -$6.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$12.60M 10-Q · filed 2026-08-05 | -$31.50M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-03-29 | -$6.40M 10-Q · filed 2026-05-06 | -$25.30M derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2024-12-31 | -$18.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$10.10M 10-K · filed 2026-02-26 | ||
| 2024-09-28 | $8.80M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $1.70M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |